Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Reviews trial data showing that the α-MSH analogue afamelanotide (Scenesse) reduces phototoxic pain and increases pain-free sunlight exposure in patients with erythropoietic protoporphyria, providing the strongest regulated clinical evidence for therapeutic melanocortin receptor agonism.

Investigated as a review (clinical pharmacology) in the field of dermatological research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.

Reviews trial data showing that the α-MSH analogue afamelanotide (Scenesse) reduces phototoxic pain and increases pain-free sunlight exposure in patients with erythropoietic protoporphyria, providing the strongest regulated clinical evidence for therapeutic melanocortin receptor agonism.

Reviews a different, regulator-approved melanocortin agonist; conclusions do not endorse unregulated Melanotan-II use.

• · PubMed: PMID 28003770 ↗
• · PubMed Central: PMC5161401 ↗
• · DOI: 10.2147/TACG.S122030 ↗
• · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
• · Google Scholar: scholar.google.com ↗